StockUS listing USCORTNASDAQHealthcareQuality Compounder

Corcept Therapeutics Incorporated(CORT) Stock Analysis | Healthcare

USD --+0.00%
Reward62Moderate
Risk13Low
75%Data
Revenue growing 32% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 13.10Bn
Reward Ratingⓘ62 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ13 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CORT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Corcept Therapeutics Incorporated?

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

AI Brief Pro

The brief on Corcept Therapeutics Incorporated

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Corcept Therapeutics Incorporated?

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 13.10B, and a P/E ratio of 263.5x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (62)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio263.4565
Beta0.401
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
586,198 shares
$3.7M
1100,000 shares
$3.3M
9-12months
11194,500 shares
$14.2M
0